Ignite Creation Date:
2024-05-06 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 2:19 PM
Study NCT ID:
NCT05140746
Status:
RECRUITING
Last Update Posted:
2024-01-09
First Post:
2021-11-08
Brief Title:
Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer
Sponsor:
Ruijin Hospital
Organization:
Ruijin Hospital
Study Overview
Official Title:
A Prospective Study on Predicting the Efficacy of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study intends to explore the value of 68Ga-FAPI-04 and 18F-FDG PETCT in the evaluation of treatment response to neoadjuvant chemotherapyNAC for patients with locally advanced gastric cancerLAGC
Detailed Description:
Before the start of NAC baseline 68Ga-FAPI-04 PETCT and 18F-FDG PETCT scans will be scheduled in all enrolled patients Next the patients with resectable LAGC will receive NAC treatment surgery will follow 36 weeks after finishing NAC Abdomen 68Ga-FAPI-04 PETCT and 18F-FDG PETCT will be scheduled after one cycle of NAC treatment or before surgery Imaging response measurements will be compared with the histopathological tumor regression grade TRG of the resection specimen as gold standard
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None